![]() We are encouraged that the initial adverse event profile exhibited by our first subject appears to be consistent with this hypothesis.” “Our hypothesis for the invention and development of Decoy20 was based on attenuation and killing of non-pathogenic bacteria to produce a product with a novel, less toxic and potentially more effective ratio of immune stimulating components. ![]() “Following dosing of our first subject in INDP-D101, we are optimistic regarding our expectations for this part of the trial,” said Michael Newman, Ph.D., the Company’s founder and chief scientific officer. A second subject in the first three-subject cohort is expected to be enrolled following final assessment of the safety and tolerability associated with dosing of the first subject, per the study protocol. After Decoy20 dosing, the subject experienced expected and manageable adverse events believed to be related to the immune system activating components known to be in the product.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |